Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6024434 | 1.00 | ESR2 (0.46) | ESR2ADORA1NR1H2MAPTKDM4E | |
| SCHEMBL9910665 | 1.00 | ESR2 (0.46) | ESR2ADORA1NR1H2MAPTKDM4E | |
| SCHEMBL20660348 | 0.92 | NR1H2 (0.42) | ESR2ADORA1NR1H2MAPTUSP2 | |
| SCHEMBL19342171 | 0.92 | NR1H2 (0.42) | ESR2ADORA1NR1H2MAPTUSP2 | |
| SCHEMBL106354 | 0.91 | USP2 (0.46) | ESR2ADORA1NR1H2MAPTKDM4E | |
| SCHEMBL428501 | 0.88 | HDAC1 (0.44) | ESR2NR1H2MAPTKDM4EUSP2 | |
| SCHEMBL3947745 | 0.86 | HPGD (0.43) | ESR2ADORA1NR1H2MAPTKDM4E | |
| SCHEMBL3947744 | 0.86 | HPGD (0.43) | ESR2ADORA1NR1H2MAPTKDM4E | |
| SCHEMBL4279524 | 0.85 | ADORA1 (0.50) | ESR2ADORA1NR1H2MAPTKDM4E | |
| SCHEMBL4279527 | 0.85 | ADORA1 (0.50) | ESR2ADORA1NR1H2MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117337280-A | Aryl heterocyclic compounds as Kv1.3 potassium SHAKER channel blockers | D·E·萧尔研究有限责任公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-109790112-B | Cyanopyrrolidine derivatives having activity as USP30 inhibitors | 特殊治疗有限公司 | 2022-08-26 | — | — | CN | disclosed |
| US-11014912-B2 | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-05-25 | — | — | US | disclosed |
| EP-3519385-B1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2020-11-18 | — | — | EP | disclosed |
| EP-3519385-A1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | Mission Therapeutics Limited (GB) | 2019-08-07 | — | — | EP | disclosed |
| WO-2018060689-A1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2018-04-05 | — | — | WO | disclosed |
| US-9814719-B2 | Methods and compositions for treating bacterial infection | CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170056405-A1 | METHODS AND COMPOSITIONS FOR TREATING BACTERIAL INFECTION | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2017-03-02 | — | — | US | disclosed |
| US-7125870-B2 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-24 | — | — | US | disclosed |
| US-20040122005-A1 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11014912-B2 | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 | USP30, USP39, USP28 | ESR2 3952/4885ADORA1 4333/4885NR1H2 3758/4885 |
| US-20170056405-A1 | METHODS AND COMPOSITIONS FOR TREATING BACTERIAL INFECTION | MMP8, RHOA, EPCAM | ESR2 3908/4885ADORA1 3510/4885NR1H2 4032/4885 |
| US-20040122005-A1 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | MMP2, MMP1, MMP9 | ESR2 1834/4885ADORA1 1729/4885NR1H2 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.